Matthew Herper on Muck Rack

Matthew Herper

Verified
New York
Senior Editor — Forbes
As seen in: Forbes

Forbes reporter covering science and medicine

GlaxoSmithKline Appoints Big Pharma's First Woman Chief Executive

forbes.com — Incoming GSK CEO Emma Walmsley GlaxoSmithKline appointed Emma Walmsley, the head of its consumer business, to become its next chief executive. She is the first woman to run a major pharmaceutical giant. Walmsley will join the board on January 1, and take command in March. She succeeds Sir Andrew Witty, who spent [...]

Approving A Muscular Dystrophy Drug Exposes A Civil War At The FDA

forbes.com — Yesterday, the Food and Drug Administration made history, approving a drug to treat Duchenne muscular dystrophy that works by targeting the genetic mutation at the root of the disease. The decision was unique for reasons that were not just scientific. Janet Woodcock, the director of the FDA's Center for Drug Evaluation [...]

Price Increases To Help Create World's First $15 Billion Medicine

forbes.com — AbbVie's Humira, used to treat rheumatoid arthritis and other auto-immune disorders, could become the world's first medicine to generate $15 billion in annual sales, according to forecasts by the investment bank Leerink. The landmark would be based partly on increased use, but even more on increases in price, writes Geoffrey Porges, Leerink's [...]

How GlaxoSmithKline Took Its Medicine

forbes.com — Andrew Witty inherited a drugmaker sick with scandal and spent the next eight years patching up his patient. GlaxoSmithKline may finally be well again.

Celgene Data Offer A Rorschach Test To Wall Street

forbes.com — For Celgene, the giant biotechnology company that turned thalidomide into a series of big-selling blood cancer drugs, the most watched event of the fall was supposed to be the release of data on GED-0301, a new treatment for Crohn's disease. In an early study, the pill seemed to induce remission [...]

Biotech's Glowing Breakthrough

forbes.com — These mice are glowing because scientists inserted a gene found in certain bioluminescent jellyfish into their DNA. That gene is a recipe for a protein that glows green when hit by blue or ultraviolet light. The protein is present throughout their bodies. As a result, their skin, eyes and organs give off an eerie light.

Novartis Dissolves CAR-T Unit, Cutting 120 Positions

forbes.com — Novartis is shutting down the business unit it created to develop white blood cells that can attack certain types of cancer, but continuing to develop such projects known as chimeric antigen receptor T-cells, or CAR-Ts. The company has not changed its plans for filing the first such product, CTL109, for children [...]

The Insurance Rip-Off At The Heart Of The EpiPen Scandal

forbes.com — Here's another rip-off about EpiPen that nobody's talking about: that there is a free market around drug prices, and many patients are being excluded from it. One of the terrifying things about the branded drug market is that competition often doesn't result in lower prices, especially when it comes to a [...]

Mad About Epipen? Here Are Some Ideas To Actually Fix America's Drug Pricing Mess

forbes.com — Mylan Pharmaceuticals has been raising the price of the EpiPen for six years. The world has been outraged about it for six days. Here, then, are some thoughts on turning the rage into change. "The reason people are upset by it is because it's upsetting," says David Maris, an analyst at [...]

Stealthy Biotech Revives Stalled Parkinson's Drug, Reveals Plans In Alzheimer's and ALS

forbes.com — Denali CEO Ryan Watts Denali Therapeutics, the stealthy South San Francisco biotech startup that raised $217 million last year to fight Alzheimer's, Parkinson's, and ALS, is finally lifting the curtain on its plans this morning. It is also announcing that it has raised another $130 million from investors in a private [...]
More Articles →
Sep 28, 2016

@davidkatz47 @JohnCendpts John is right, generally, but nicely written tweet.

Sep 28, 2016

RT @annaedney: Health insurer Cigna to cover Sarepta's Exondys for Duchenne muscular dystrophy. Price is ~$300k/yr. Via @ZTracer and @FayCortez

Sep 28, 2016

RT @megtirrell: Senators ask Justice Dept to investigate $MYL, citing evidence MYL may have knowingly misclassified #EpiPen: https://t.co/blxSQ6013u

Sep 27, 2016

@charlesornstein @VinayPrasad82 @ScottGottliebMD @DShaywitz I also know great former journos who are now in PR. Which is more analogous.


Are You a Journalist?

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Create a Portfolio